Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysisCapsule Summary

Thomas Graier, MD; Wolfgang Weger, MD; Paul-Gunther Sator, MD; Wolfgang Salmhofer, MD; Barbara Gruber, MD; Constanze Jonak, MD; Claudia Kölli, MD; Martina Schütz-Bergmayr, MD; Igor Vujic, MD; Gudrun Ratzinger, MD; Nina Häring, MD; Clemens Painsi, MD, PhD; Knut Prillinger, MD; Alexander Mlynek, MD; Hans Skvara, MD; Hannes Trattner, MD; Adrian Tanew, MD; Roland Lichem, MD; Christina Ellersdorfer, MD; Franz Legat, MD; Alexandra Gruber-Wackernagel, MD; Angelika Hofer, MD; Erich Schmiedberger, MSc; Wolfram Hoetzenecker, MD, PhD; Robert Müllegger, MD; Werner Saxinger, MD; Franz Quehenberger, PhD; Peter Wolf, MD

JAAD International (Mar 2021)

Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysisCapsule Summary

Thomas Graier, MD,
Wolfgang Weger, MD,
Paul-Gunther Sator, MD,
Wolfgang Salmhofer, MD,
Barbara Gruber, MD,
Constanze Jonak, MD,
Claudia Kölli, MD,
Martina Schütz-Bergmayr, MD,
Igor Vujic, MD,
Gudrun Ratzinger, MD,
Nina Häring, MD,
Clemens Painsi, MD, PhD,
Knut Prillinger, MD,
Alexander Mlynek, MD,
Hans Skvara, MD,
Hannes Trattner, MD,
Adrian Tanew, MD,
Roland Lichem, MD,
Christina Ellersdorfer, MD,
Franz Legat, MD,
Alexandra Gruber-Wackernagel, MD,
Angelika Hofer, MD,
Erich Schmiedberger, MSc,
Wolfram Hoetzenecker, MD, PhD,
Robert Müllegger, MD,
Werner Saxinger, MD,
Franz Quehenberger, PhD,
Peter Wolf, MD

Affiliations

Thomas Graier, MD: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
Wolfgang Weger, MD: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
Paul-Gunther Sator, MD: Department of Dermatology, Hietzing Hospital, Vienna, Austria
Wolfgang Salmhofer, MD: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
Barbara Gruber, MD: Department of Dermatology and Venereology, Hospital of Wels-Grieskirchen, Wels-Grieskirchen, Austria
Constanze Jonak, MD: Department of Dermatology, Medical University of Vienna, Vienna, Austria
Claudia Kölli, MD: Department of Dermatology and Venereology, State Hospital, Wiener Neustadt, Austria
Martina Schütz-Bergmayr, MD: Department of Dermatology and Venereology, Kepler University Hospital, Linz, Austria
Igor Vujic, MD: Department of Dermatology and Venereology, State Hospital of Vienna Rudolfstiftung, Vienna, Austria
Gudrun Ratzinger, MD: Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria
Nina Häring, MD: Department of Dermatology and Venereology, Federal Academic Teaching Hospital, Feldkirch, Austria
Clemens Painsi, MD, PhD: Department of Dermatology and Venereology, State Hospital, Klagenfurt, Austria
Knut Prillinger, MD: Department of Dermatology and Venereology, University Hospital St. Pölten, Sankt Pölten, Austria
Alexander Mlynek, MD: Department of Dermatology, Hospital of Elisabethinen, Linz, Austria
Hans Skvara, MD: Department of Dermatology and Venereology, State Hospital, Wiener Neustadt, Austria
Hannes Trattner, MD: Department of Dermatology, Medical University of Vienna, Vienna, Austria
Adrian Tanew, MD: Department of Dermatology, Medical University of Vienna, Vienna, Austria
Roland Lichem, MD: Department of Dermatology and Venereology, Kepler University Hospital, Linz, Austria
Christina Ellersdorfer, MD: Department of Dermatology and Venereology, State Hospital of Vienna Rudolfstiftung, Vienna, Austria
Franz Legat, MD: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
Alexandra Gruber-Wackernagel, MD: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
Angelika Hofer, MD: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
Erich Schmiedberger, MSc: Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria
Wolfram Hoetzenecker, MD, PhD: Department of Dermatology and Venereology, Kepler University Hospital, Linz, Austria
Robert Müllegger, MD: Department of Dermatology and Venereology, State Hospital, Wiener Neustadt, Austria
Werner Saxinger, MD: Department of Dermatology and Venereology, Hospital of Wels-Grieskirchen, Wels-Grieskirchen, Austria
Franz Quehenberger, PhD: Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria
Peter Wolf, MD: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria; Correspondence to: Peter Wolf, MD, Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, Graz, A-8036, Austria.

Journal volume & issue: Vol. 2
pp. 62 – 75

Abstract

Read online

Background: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions. Objective: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction. Methods: This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry. Results: Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively. Limitations: Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment. Conclusion: Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.

Published in JAAD International

ISSN: 2666-3287 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Dermatology
Website: https://www.journals.elsevier.com/jaad-international

About the journal

Abstract

Keywords